Administration Case Report With EXPAREL

This case report represents the individual experience of Dr Alexander P. Sah and is intended to demonstrate his methodology for using EXPAREL in an anterior total hip replacement.

Pacira BioSciences, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations when selecting the dose for a specific procedure.

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

**CASE INFORMATION**

<table>
<thead>
<tr>
<th>Physician Name</th>
<th>Alexander P. Sah, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliation</td>
<td>Sah Orthopaedic Associates; Medical Co-director, Institute for Joint Restoration; Director, Outpatient Joint Replacement Program; Chair, IJRR Research and Education Committee, Fremont, CA</td>
</tr>
<tr>
<td>Surgical Case Performed</td>
<td>Total hip replacement, anterior approach</td>
</tr>
<tr>
<td>Inpatient or Outpatient Procedure</td>
<td>Outpatient</td>
</tr>
</tbody>
</table>

**PATIENT CHARACTERISTICS**

| Gender | Male |
| Age   | 70 years |
| Patient History and Characteristics | Patient presented with worsening right hip pain and concomitant limitations, as well as chronic increasing groin pain. X-rays confirmed bone-on-bone OA. Patient underwent a successful left THR with a mini-posterior approach 16 months prior and was now prepared to proceed with a right THR using an anterior approach. |

**PROCEDURAL DETAILS**

| Incision Size  | 8 to 10 cm |
| Preoperative Medications Used | IV dexamethasone 10 mg, IV TXA 1 g |
| Preoperative Analgesics Used | PO 200 mg celecoxib, PO tramadol 100 mg, PO pregabalin 75 mg, IV acetaminophen 1 g |
| Intraoperative Analgesics Used | Upon induction of general anesthesia, 80 mL of expanded EXPAREL for local infiltration |

**Dose of EXPAREL and Total Volume Used**

<table>
<thead>
<tr>
<th>EXPAREL (266 mg)</th>
<th>Bupivacaine HCl 0.5%</th>
<th>Normal Saline</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 mL</td>
<td>30 mL</td>
<td>30 mL</td>
<td>80 mL</td>
</tr>
</tbody>
</table>

IV, intravenous; OA, osteoarthritis; PO, by mouth; THR, total hip replacement; TXA, tranexamic acid.

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg.

EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.

Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physicochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurologic and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on the last page and refer to accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
For a total hip replacement (anterior approach), the EXPAREL injectate should be infiltrated as follows: 40% in the deep tissues, 40% in the mid-level/anterior tissues, and 20% in the superficial tissues.

**ASSESSED THE SIZE OF THE SURGICAL SITE AND DEPTH OF TISSUE, THEN PREPARED INJECTION MATERIALS ACCORDINGLY**

In this procedure, Dr Sah determined a total volume of 80 mL would be needed to cover the surgical site. He expanded 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 30 mL of normal saline and admixed this solution with 30 mL of 0.5% bupivacaine HCl. Bupivacaine HCl was admixed to provide short-term local analgesia in the postanesthesia care unit that overlapped with the long-term local analgesia provided by EXPAREL.

**DIVIDED INJECTATE INTO MULTIPLE SYRINGES WITH NEEDLE SIZES APPROPRIATE FOR INFILTRATION (20 TO 25 GAUGE) AND INFILTRATED INTO THE SURGICAL SITE**

Dr Sah divided the EXPAREL injectate into four 20-mL syringes with 22-gauge needles.

- **Step #1:** Deep tissues
- **Step #2:** Mid-level/anterior tissues
- **Step #3:** Superficial tissues
Step #1:
Before placing the prosthesis, Dr Sah infiltrated 32 mL of expanded EXPAREL into the deep tissues surrounding the capsule (anterior capsule, superior capsule, posterior capsule, deep anterolateral capsule, psoas tendon), the obturator externus, and the periosteum.

Care should be taken not to inject into the tissue posterior to the hip capsule due to the proximity of the sciatic nerve.

Step #2:
After placing the prosthesis, Dr Sah infiltrated 32 mL of expanded EXPAREL into the mid-level/anterior target sites superficial to the deeper capsular structures. These included the gluteus medius and minimus muscles, the rectus femoris muscle, the tensor fascia lata muscle, and the sartorius muscle.

Step #3:
Dr Sah then injected 16 mL into the superficial fascia, subcutaneous layer, and skin surrounding the surgical site.
**Important Safety Information**

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

**Warnings and Precautions Specific to EXPAREL**

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

**Warnings and Precautions for Bupivacaine-Containing Products**

**Central Nervous System (CNS) Reactions:** There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

**Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

**Allergic Reactions:** Allergic-type reactions (e.g., anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

**Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

**Methemoglobinemia:** Cases of methemoglobinemia have been reported with local anesthetic use.

**Disclosure:** Dr Sah is a paid consultant for Pacira BioSciences, Inc.